UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
December 28, 1998
-----------------------------------------
(Date of earliest event reported)
Cephalon, Inc.
--------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-19119 23-2484489
- ----------------------------------- ----------- -------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation or organization) File Number) ID No.)
145 Brandywine Parkway
West Chester, Pennsylvania 19380
-------------------------- -----------------
(Address of principal executive offices) (Zip Code)
(215) 344-0200
--------------------------------------------------------------------
(Registrant's telephone number, including area code)
Not Applicable
------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
ITEM 5. OTHER EVENTS.
On December 28, 1998, Cephalon, Inc. (the "Registrant") publicly announced
that the U.S. Food & Drug Administration (the "FDA") approved its drug
PROVIGIL(R) (modafinil) Tablets [C-IV], for the treatment of excessive daytime
sleepiness associated with Narcolepsy.
The Registrant hereby incorporates by reference the press release attached
hereto as Exhibit 99.1 and made a part hereof, into this Item 5.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements of Business Acquired: None
------------------------------------------
(b) Pro Forma Financial Information: None
--------------------------------
(c) Exhibits: Reference is made to the Exhibit Index annexed hereto and
--------
made a part hereof.
SIGNATURES
-----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CEPHALON, INC.
Date: December 28, 1998 By: /s/ Bruce A. Peacock
----------------- ------------------------------
Bruce A. Peacock
Executive Vice President and
Chief Operating Officer
EXHIBIT INDEX
-------------
EXHIBIT PAGE
- ------- ----
99.1 Press Release dated December 28, 1998